H&H INTL HLDG (01112) announced that its subsidiary has been granted approximately $320 million in term loan financing and approximately $10 million in revolving credit financing.

H&H International Holdings (01112) announced that on August 5, 2026, the company and Biostime Healthy Australia Investment Pty Ltd (a wholly-owned subsidiary of the company) (as the original borrower) entered into a syndicate financing agreement (refinancing credit agreement) with The Hongkong and Shanghai Banking Corporation Limited (as the agent and collateral agent) to provide a term loan financing amounting to approximately USD 320 million (term loan financing); and a revolving credit financing amounting to approximately USD 10 million (revolving financing, collectively referred to as "refinancing credit" with the term loan financing), totaling approximately USD 330 million.